Stocktoria

Scinai Immunotherapeutics Ltd. SCNI

Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2007-06-07

Scinai Immunotherapeutics Ltd. statistics & valuation

Market cap$887,408
P / S0.7×
P / B0.1×
Net margin-633.6%
Return on equity-102.5%
FCF margin-461.9%
Return on capital-75.1%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Net margin (%)
728.90% -633.60% 20212022202320242025
Gross margin (%)
-88.10% -202.30% 20212022202320242025
Operating margin (%)
-1312.80% -575.30% 20212022202320242025
Return on equity (%)
-835.60% 48.10% -102.50% 20212022202320242025
Shares outstanding
739.0M 989.3M 1.86B 3.41B 13.87B 20212022202320242025
Net debt ($)
20212022202320242025
Share buybacks ($)
20212022202320242025
Return on assets (%)
-25.60% -21.40% -37.20% 35.70% -71.50% 20212022202320242025
Free cash flow margin (%)
-964.60% -461.90% 20212022202320242025
Debt / equity (×)
20212022202320242025
EPS ($)
-$0.02 $0.01 $0.00 20212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021
Gross margin-202.3%-88.1%———
Operating margin-575.3%-1312.8%———
Net margin-633.6%728.9%———
FCF margin-461.9%-964.6%———
Return on assets-71.5%35.7%-37.2%-21.4%-25.6%
Return on equity-102.5%48.1%142.3%329.3%-835.6%
Current ratio1.301.323.066.157.30

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.